Quick Answer
Autolus Therapeutics plc reported Research And Development Expense of $117.69 million for the year ending 2025.
- Autolus Therapeutics plc showed a decrease of -15.0% in Research And Development Expense from 2024 to 2025.
- This data is from Autolus Therapeutics plc's annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Autolus Therapeutics plc's Research And Development Expense has grown by 1,027.7%.
- Historical annual values: Fiscal year 2025: $117.69 million | Fiscal year 2024: $138.44 million | Fiscal year 2023: $130.48 million | Fiscal year 2022: $117.35 million | Fiscal year 2021: $110.84 million | Fiscal year 2020: $134.89 million | Fiscal year 2019: $105.42 million | Fiscal year 2018: $36.15 million | Fiscal year 2017: $16.01 million | Fiscal year 2016: $10.44 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: